Efficient generation of epitope-targeted de novo antibodies with Germinal

Obtaining novel antibodies against specific protein targets is a widely important yet experimentally laborious process. Meanwhile, computational methods for antibody design have been limited by low success rates that currently require resource-intensive screening. Here, we introduce Germinal, a broadly enabling generative framework that designs antibodies against specific epitopes with nanomolar binding affinities while requiring only low-throughput experimental testing. Our method co-optimizes antibody structure and sequence by integrating a structure predictor with an antibody-specific protein language model to perform de novo design of functional complementarity-determining regions (CDRs) onto a user-specified structural framework. When tested against four diverse protein targets, Germinal achieved an experimental success rate of 4-22% across all targets, testing only 43-101 designs for each antigen. Validated nanobodies also exhibited robust expression in mammalian cells and nanomolar binding affinities. We provide open-source code and full computational and experimental protocols to facilitate wide adoption. Germinal represents a milestone in low-throughput, epitope-targeted de novo antibody design, with notable implications for the development of molecular tools and therapeutics.